Autopsy report · NCT00956072

Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“low accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 3 months after it had already started.
12 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Sponsor type: University, hospital or other
Conditions: Gastrointestinal Stromal Tumor
Interventions: imatinib mesylate; therapeutic conventional surgery
Participants: 12
Sites: 1
Countries: Italy

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.